<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Comorbidities that impact management of osteoarthritis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Comorbidities that impact management of osteoarthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Comorbidities that impact management of osteoarthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karine Louati, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Hunter, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4038601596"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteoarthritis (OA) is the most common form of arthritis and can often be disabling in adults. Although many drugs are available for the symptomatic treatment of OA, the presence of comorbidities complicates management and remains a practical challenge. Both nonpharmacologic and pharmacologic interventions may require adaptation depending on the comorbidity.</p><p>This topic will review the management of OA in patients with common comorbidities. The pathogenesis and risk factors, diagnosis, clinical manifestations, and treatment of OA are presented separately. (See  <a class="medical medical_review" href="/d/html/5498.html" rel="external">"Pathogenesis of osteoarthritis"</a> and  <a class="medical medical_review" href="/d/html/5499.html" rel="external">"Epidemiology and risk factors for osteoarthritis"</a> and  <a class="medical medical_review" href="/d/html/105723.html" rel="external">"Clinical manifestations and diagnosis of osteoarthritis"</a> and  <a class="medical medical_review" href="/d/html/106097.html" rel="external">"Overview of the management of osteoarthritis"</a> and  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis"</a> and  <a class="medical medical_review" href="/d/html/112192.html" rel="external">"Management of moderate to severe knee osteoarthritis"</a>.)</p><p class="headingAnchor" id="H1743140095"><span class="h1">BACKGROUND</span><span class="headingEndMark"> — </span>The prevalence of comorbidities among patients with osteoarthritis (OA) is high. In a meta-analysis with 42 studies, the prevalence of any comorbidity was 67 percent (95% CI 57-74) in individuals with OA versus 56 percent (95% CI 44-68) without OA [<a href="#rid1">1</a>]. The leading chronic conditions among patients with OA included hypertension in 50 percent, cardiovascular disease in 35 percent, peptic ulcer disease in 16 percent, and diabetes in 14 percent. In another meta-analysis, diabetes is also a relatively common comorbidity among patients with OA, with estimates of prevalence of approximately 15 percent [<a href="#rid2">2</a>]. Other studies have shown that the metabolic syndrome is more frequent in patients with OA compared with controls [<a href="#rid3">3,4</a>].</p><p>The prevalence of cardiovascular disease (CVD) among patients with OA is also high. A meta-analysis including over 32,000,000 patients with OA found that they were twice as likely to have CVD [<a href="#rid5">5</a>]. Several studies have also suggested that OA is associated with excess mortality risk due to CVD, diabetes mellitus (DM), obesity, cognitive disorders, and disability [<a href="#rid6">6-8</a>] (see  <a class="medical medical_review" href="/d/html/106097.html" rel="external">"Overview of the management of osteoarthritis", section on 'Mortality'</a>). In addition, pain secondary to OA may promote hypertension, obesity, and CVD by decreasing mobility (sometimes called the "sitting disease"). In an analysis including 10,723 patients with knee OA, the presence of pain had a 37 percent increased association with reduced time-to-morality in an adjusted model [<a href="#rid8">8</a>]. Finally, greater comorbidity burden with cardiac disease, diabetes, or back pain has been shown to contribute to worse pain and physical function in patients with knee and/or hip OA [<a href="#rid9">9</a>]. Findings from a systematic review suggest that having at least one comorbidity is one of the factors associated with a worse evolution of pain over several years [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H1163198338"><span class="h1">MANAGEMENT CONSIDERATIONS FOR COMORBIDITIES</span><span class="headingEndMark"> — </span>The presence of comorbidities in patients with osteoarthritis (OA) often impacts treatment choices, particularly with respect to pharmacologic therapy. Among these agents, the use of oral nonsteroidal antiinflammatory drugs (NSAIDs) is often limited due to the increased risk of adverse effects in patients with common comorbidities. When possible, NSAIDs should be used for the shortest period of time, the efficacy decreasing after a couple of weeks, whereas the incidence of side effects increases over time [<a href="#rid11">11</a>]. Otherwise, the same general management principles of OA should apply, in that all patients should also engage in nonpharmacologic measures such as weight management and exercise, braces, walking aids, and psychological interventions as appropriate. It is worth noting that the beneficial effects of exercise and weight loss are not only limited to OA but are also advantageous for several other comorbidities.</p><p>We discuss specific considerations when managing OA in the setting of the common comorbidities listed below. Our approach to managing OA patients with comorbidities is generally consistent with those that have been addressed by major guidelines [<a href="#rid12">12-14</a>].</p><p class="headingAnchor" id="H2740204918"><span class="h2">Diabetes mellitus</span><span class="headingEndMark"> — </span>We avoid the use of oral NSAIDs when treating OA patients with diabetes mellitus (DM), particularly among those with complications such as cardiovascular disease (CVD) and/or kidney disease. Adverse effects of NSAIDs among patients with kidney disease and CVD are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a> and  <a class="medical medical_review" href="/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a>.)</p><p>Other oral pharmacologic agents and supplements used in the treatment of OA appear to be safe, but few have been studied specifically in the context of DM. There are some data that support the safety of glucosamine among patients with DM. An analysis of safety data from one randomized trial found that the mean plasma glucose levels in the group of patients taking glucosamine did not differ from baseline at both the three- and six-month follow-up period [<a href="#rid15">15</a>]. Also, a subgroup analysis of hyperglycemic patients at baseline found that mean glucose levels tended to decrease over time with glucosamine compared with placebo. Additional information regarding the use of glucosamine and chondroitin for OA can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Nutritional supplements'</a>.)</p><p>Intraarticular glucocorticoid injections pose a theoretical risk to patients with DM by potentially raising blood glucose to hyperglycemic levels. However, patients generally experience an isolated increase in blood glucose for one to two days after the injection which rarely poses a significant clinical risk when DM is well controlled. For insulin-dependent diabetic patients in whom an intraarticular injection is warranted, self-monitoring of blood glucose should be performed for up to three to five days after the injection. In a case–crossover study of 40 patients with type 1 or 2 DM, the fasting blood glucose level was increased one and two days after a glucocorticoid injection for common conditions in the hand and wrist (eg, trigger finger, carpal tunnel syndrome, OA), especially in insulin-dependent diabetic patients. Fasting blood glucose concentration did not differ after the second post-injection day. [<a href="#rid16">16</a>]. In another study with 23 patients with DM, an extraarticular wrist injection of 10 mg of <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide increased blood glucose levels during five days after injection as compared with morning blood glucose levels pre-injection [<a href="#rid17">17</a>]. Insulin-dependent patients experienced greater changes from baseline compared with non-insulin–dependent patients. Additional information regarding the use of intraarticular glucocorticoid injections in the management of knee OA is discussed separately. (See  <a class="medical medical_review" href="/d/html/112192.html" rel="external">"Management of moderate to severe knee osteoarthritis", section on 'Limited role of intraarticular glucocorticoid injections'</a>.)</p><p class="headingAnchor" id="H722719391"><span class="h2">Poorly controlled hypertension</span><span class="headingEndMark"> — </span>We generally limit the use of oral NSAIDs in OA patients with hypertension to those whose hypertension is well controlled and who have preserved kidney function. All NSAIDs at therapeutic doses can increase blood pressure in both normotensive and hypertensive individuals. Cyclooxygenase (COX)-2 inhibitor NSAIDs seem to have the more pro-hypertensive effects than nonselective NSAIDs [<a href="#rid18">18</a>]. In a meta-analysis which measured the hypertensive effects of various nonselective NSAIDs, <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>, and <a class="drug drug_general" data-topicid="9781" href="/d/drug information/9781.html" rel="external">piroxicam</a> appeared to have a greater effect on increasing blood pressure relative to <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> and <a class="drug drug_general" data-topicid="9967" href="/d/drug information/9967.html" rel="external">sulindac</a> [<a href="#rid19">19</a>]. NSAID use may also reduce the effect of all antihypertensive drugs except calcium channel blockers. A detailed discussion of the effect of NSAIDs on blood pressure is presented separately. (See  <a class="medical medical_review" href="/d/html/2385.html" rel="external">"NSAIDs and acetaminophen: Effects on blood pressure and hypertension"</a>.)</p><p>Although <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> is no longer a preferred agent in the management of OA, it is not contraindicated in OA patients with hypertension. While there have also been some studies suggesting an increased effect on blood pressure with acetaminophen [<a href="#rid20">20</a>], the data are mixed, with most studies reporting no effect [<a href="#rid15">15,21-23</a>]. (See  <a class="medical medical_review" href="/d/html/2385.html" rel="external">"NSAIDs and acetaminophen: Effects on blood pressure and hypertension"</a>.)</p><p>Intraarticular glucocorticoid injections do not appear to have a significant effect on blood pressure, based largely on data from patients with rheumatoid arthritis [<a href="#rid24">24-26</a>]. However, considering the known effects of systemic glucocorticoids on blood pressure, the blood pressure may be evaluated for the three to five days after the injection in patients with poorly controlled hypertension.</p><p class="headingAnchor" id="H666209427"><span class="h2">Cardiovascular disease</span><span class="headingEndMark"> — </span>In patients with CVD, the use of both selective and nonselective NSAIDs should be avoided [<a href="#rid27">27</a>]. For those patients in whom an NSAID is necessary, the choice is influenced by other factors which include the presence of other comorbidities and the cost to the patient. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects", section on 'Patients with known coronary heart disease'</a> and  <a class="medical medical_review" href="/d/html/7993.html" rel="external">"NSAIDs: Therapeutic use and variability of response in adults", section on 'NSAID use and comorbidities'</a> and  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects", section on 'NSAID characteristics'</a>.)</p><p>Regular NSAID use should also be avoided in patients taking low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> for cardiovascular protection. In patients on aspirin who require NSAIDs on an occasional short-term basis, aspirin should be taken at least two hours before the NSAID. (See  <a class="medical medical_review" href="/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a> and  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects", section on 'Aspirin and other antithrombotic agents'</a>.)</p><p>Patients with OA and walking disability are at increased risk of death from cardiovascular causes [<a href="#rid6">6</a>]. Thus, management of OA in patients with CVD should focus on approaches that will improve walking disability [<a href="#rid6">6</a>]. Nonpharmacologic therapies including exercises, braces, education, and the use of assistive devices such as canes should be emphasized. Moreover, cardiovascular rehabilitation programs that increase physical activity have a positive impact on both CVD and OA. The benefits and risks of exercise in patients with CVD as well as an approach to prescribing exercise are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1552.html" rel="external">"Cardiac rehabilitation: Indications, efficacy, and safety in patients with coronary heart disease"</a>.)</p><p>Among pharmacologic treatments that are commonly used to treat OA, we prefer local treatments including topical agents (eg, topical NSAIDs, <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a>) and intraarticular glucocorticoid injections rather than systemic therapies for patients with CVD. However, when appropriate, other systemic therapies used in the treatment of OA such as <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> can be used in patients with CVD. (See  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Topical NSAIDs'</a> and  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Topical capsaicin'</a> and  <a class="medical medical_review" href="/d/html/112192.html" rel="external">"Management of moderate to severe knee osteoarthritis", section on 'Duloxetine'</a> and  <a class="medical medical_review" href="/d/html/112192.html" rel="external">"Management of moderate to severe knee osteoarthritis", section on 'Limited role of intraarticular glucocorticoid injections'</a>.)</p><p>There are limited data regarding cardiovascular effects with analgesics other than NSAIDs, most of which are limited to <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>. As mentioned above, acetaminophen is no longer a preferred agent for the treatment of OA [<a href="#rid28">28</a>]. There are conflicting data on the effect of acetaminophen on cardiovascular disease [<a href="#rid28">28-31</a>]. A large population-based study including 10,878 patients over the age of 65 who were exposed to acetaminophen during a 10-year period found that there was no associated increased risk of myocardial infarction or stroke [<a href="#rid30">30,31</a>]. However, a systemic review which included four observational studies with data on adverse cardiovascular events found a dose-response increase with acetaminophen in the risk ratio of cardiovascular adverse events in each of the studies [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Acetaminophen'</a>.)</p><p>Opioids have been associated with an increased risk of myocardial infarction when used long-term and should only be limited to short-term use in OA patients with severe and disabling symptoms in whom other interventions have failed [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain", section on 'Monitoring for adverse effects'</a>.)</p><p class="headingAnchor" id="H3101813587"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>We avoid the use of NSAIDs in the management of OA patients with chronic kidney disease, especially stages 3 and 4, given the risk of contributing to chronic kidney disease progression. A detailed discussion of the NSAIDs and their effect on kidney function is presented separately. (See  <a class="medical medical_review" href="/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a> and  <a class="medical medical_review" href="/d/html/93774.html" rel="external">"Management of chronic pain in advanced chronic kidney disease", section on 'Drugs that should be avoided'</a>.)</p><p>Among pharmacologic treatments that are commonly used to treat OA, we prefer local treatments including topical agents (eg, topical NSAIDs, <a class="drug drug_general" data-topicid="8840" href="/d/drug information/8840.html" rel="external">capsaicin</a>) and intraarticular glucocorticoid injections rather than systemic therapies in patients with chronic kidney disease. (See  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Topical NSAIDs'</a> and  <a class="medical medical_review" href="/d/html/112192.html" rel="external">"Management of moderate to severe knee osteoarthritis", section on 'Limited role of intraarticular glucocorticoid injections'</a>.)</p><p class="headingAnchor" id="H362639548"><span class="h2">Peptic ulcer disease</span><span class="headingEndMark"> — </span>The recurrence of ulcer complications with continued use of NSAIDs is well-established and is contraindicated when treating OA patients with active peptic ulcer disease (eg, active bleeding or perforation). (See  <a class="medical medical_review" href="/d/html/24.html" rel="external">"Overview of complications of peptic ulcer disease", section on 'Discontinue NSAIDs'</a>.)</p><p>In patients with a history of peptic ulcer disease or at elevated risk for gastroduodenal disease who require NSAIDs, we combine an NSAID with a gastroprotective agent (eg, a proton pump inhibitor). COX-2 inhibitors may be safer than nonselective NSAIDs for reduction in the risk of gastrointestinal bleeding but are still associated with an increased risk. The relative gastrointestinal toxicity of different NSAIDs and prevention of NSAID-induced gastroduodenal damage are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/14.html" rel="external">"NSAIDs (including aspirin): Treatment and secondary prevention of gastroduodenal toxicity"</a>.)</p><p class="headingAnchor" id="H3997438495"><span class="h2">Obesity</span><span class="headingEndMark"> — </span>The importance of weight loss should be emphasized for all OA patients who are overweight or obese. Obesity is associated with lower-limb and hand OA and can worsen pain and functional disability [<a href="#rid33">33,34</a>]. Obesity also has a direct mechanical effect on weightbearing joints, as do various substances in adipose tissue such as adipokines or inflammatory proteins (see  <a class="medical medical_review" href="/d/html/5498.html" rel="external">"Pathogenesis of osteoarthritis", section on 'Risk factors'</a>). The approach to the management of obesity is discussed separately. (See  <a class="medical medical_review" href="/d/html/5371.html" rel="external">"Obesity in adults: Overview of management"</a>.)</p><p>Weight loss has been shown to reduce both pain and disability in patients with knee OA. As an example, in a randomized trial with 399 patients with knee OA and obesity, the association of diet-induced weight loss (≥10 percent) and physical exercise for 18 months was more effective on pain and mobility than each intervention alone [<a href="#rid35">35</a>]. In a meta-analysis of 19 randomized trials of patients with knee or hip OA, weight reduction was found to provide small to moderate improvement in pain and disability [<a href="#rid36">36</a>]. There is also some evidence to suggest that weight loss may have a structural effect on OA. In a study with 112 patients with obesity, weight loss was associated with reduced medial-tibial cartilage volume loss (but not lateral and patella cartilage) and improved knee symptoms (pain, stiffness, and function) [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H2943564325"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H3864378755"><span class="h2">Older age</span><span class="headingEndMark"> — </span>In older adults with osteoarthritis (OA), optimizing drug therapy is more challenging. Analgesics have pharmacokinetics characteristics different from those of younger patients and the risk of toxicity is increased. Pharmacologic therapies that are sometimes used to treat OA symptoms which may be more likely to result in adverse effects include nonsteroidal antiinflammatory drugs (NSAIDs), <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, and opioids. (See  <a class="medical medical_review" href="/d/html/3013.html" rel="external">"Drug prescribing for older adults"</a>.)</p><p>The metabolism of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> in older patients is highly variable and may be reduced in frail older patients due to a decreased volume of distribution and intrinsic conjugative activity of the liver [<a href="#rid38">38</a>]. Thus, older adults may be at increased risk of hepatotoxicity, and the maximum daily dose should likely be reduced to between 2 and 3 g/day (see  <a class="medical medical_review" href="/d/html/2798.html" rel="external">"Cancer pain management: Use of acetaminophen and nonsteroidal anti-inflammatory drugs", section on 'Hepatic toxicity'</a>). NSAIDs have also been shown to increase the risk of gastrointestinal, cardiovascular, and renal adverse effects in older adults [<a href="#rid38">38</a>] (see  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a> and  <a class="medical medical_review" href="/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs", section on 'Toxicities and possible toxicities'</a>). Opioid use in older adults is associated with an increased risk of cognitive impairment, delirium, or injuries (eg, falls, fractures) and may also increase the risk of cardiovascular events, pneumonia, hospitalization, and mortality [<a href="#rid38">38,39</a>]. (See  <a class="medical medical_review" href="/d/html/16525.html" rel="external">"Treatment of chronic non-cancer pain in older adults", section on 'Opioids'</a>.)</p><p class="headingAnchor" id="H4114603164"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113788.html" rel="external">"Society guideline links: Osteoarthritis"</a>.)</p><p class="headingAnchor" id="H3863986936"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – The presence of comorbidities in patients with osteoarthritis (OA) often impacts treatment choices, particularly with respect to pharmacologic therapy. (See <a class="local">'Background'</a> above and <a class="local">'Management considerations for comorbidities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management considerations for comorbidities</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diabetes mellitus</strong> – We avoid the use of oral nonsteroidal antiinflammatory drugs (NSAIDs) when treating OA patients with diabetes mellitus (DM), particularly among those with complications such as cardiovascular disease (CVD) and/or kidney disease. (See <a class="local">'Diabetes mellitus'</a> above and  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a> and  <a class="medical medical_review" href="/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a>.)</p><p></p><p class="bulletIndent2">Intraarticular glucocorticoid injections pose a theoretical risk to patients with DM by potentially raising blood glucose to hyperglycemic levels. However, patients generally experience an isolated increase in blood glucose for one to two days after the injection, which rarely poses a significant clinical risk when DM is well controlled. For insulin-dependent diabetic patients in whom an intraarticular injection is warranted, self-monitoring of blood glucose should be performed for up to three to five days after the injection. (See <a class="local">'Diabetes mellitus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Poorly controlled hypertension</strong> – We generally limit the use of oral NSAIDs in OA patients with hypertension to those whose hypertension is well controlled and who have preserved kidney function. (See <a class="local">'Poorly controlled hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiovascular disease</strong> – In patients with CVD, the use of both selective and nonselective NSAIDs should be avoided. For those patients in whom an NSAID is necessary, the choice is influenced by other factors which include the presence of other comorbidities and the cost to the patient. (See <a class="local">'Cardiovascular disease'</a> above and  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects", section on 'Patients with known coronary heart disease'</a> and  <a class="medical medical_review" href="/d/html/7993.html" rel="external">"NSAIDs: Therapeutic use and variability of response in adults", section on 'NSAID use and comorbidities'</a> and  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects", section on 'NSAID characteristics'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic kidney disease</strong> – We avoid the use of NSAIDs in the management of OA patients with chronic kidney disease, especially stages 3 and 4, given the risk of contributing to chronic kidney disease progression. (See <a class="local">'Chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Peptic ulcer disease</strong> – In patients with a history of peptic ulcer disease or at elevated risk for gastroduodenal disease who require NSAIDs, we combine an NSAID with a gastroprotective agent (eg, a proton pump inhibitor). (See  <a class="medical medical_review" href="/d/html/14.html" rel="external">"NSAIDs (including aspirin): Treatment and secondary prevention of gastroduodenal toxicity"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Obesity</strong> – The importance of weight loss should be emphasized for all OA patients who are overweight or obese. Obesity is associated with lower-limb and hand OA and can worsen pain and functional disability. (See <a class="local">'Obesity'</a> above and  <a class="medical medical_review" href="/d/html/111177.html" rel="external">"Management of knee osteoarthritis", section on 'Weight loss'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Older age</strong> – In older adults with OA, optimizing drug therapy is more challenging. Analgesics have pharmacokinetics characteristics different from those of younger patients and the risk of toxicity is increased. Pharmacologic agents for treating OA-related pain which may be more likely to result in adverse effects include NSAIDs, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, and opioids. (See <a class="local">'Older age'</a> above.)</p><p></p><p class="headingAnchor" id="H4291378369"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Francis Berenbaum, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Swain S, Sarmanova A, Coupland C, et al. Comorbidities in Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studies. Arthritis Care Res (Hoboken) 2020; 72:991.</a></li><li><a class="nounderline abstract_t">Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open 2015; 1:e000077.</a></li><li><a class="nounderline abstract_t">Calvet J, Orellana C, Larrosa M, et al. High prevalence of cardiovascular co-morbidities in patients with symptomatic knee or hand osteoarthritis. Scand J Rheumatol 2015; :1.</a></li><li><a class="nounderline abstract_t">Visser AW, de Mutsert R, le Cessie S, et al. The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study. Ann Rheum Dis 2015; 74:1842.</a></li><li><a class="nounderline abstract_t">Hall AJ, Stubbs B, Mamas MA, et al. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23:938.</a></li><li><a class="nounderline abstract_t">Nüesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011; 342:d1165.</a></li><li><a class="nounderline abstract_t">Hawker GA, Croxford R, Bierman AS, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PLoS One 2014; 9:e91286.</a></li><li><a class="nounderline abstract_t">Leyland KM, Gates LS, Sanchez-Santos MT, et al. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res 2021; 33:529.</a></li><li><a class="nounderline abstract_t">Calders P, Van Ginckel A. Presence of comorbidities and prognosis of clinical symptoms in knee and/or hip osteoarthritis: A systematic review and meta-analysis. Semin Arthritis Rheum 2018; 47:805.</a></li><li><a class="nounderline abstract_t">Previtali D, Andriolo L, Di Laura Frattura G, et al. Pain Trajectories in Knee Osteoarthritis-A Systematic Review and Best Evidence Synthesis on Pain Predictors. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Osani MC, Vaysbrot EE, Zhou M, et al. Duration of Symptom Relief and Early Trajectory of Adverse Events for Oral Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) 2020; 72:641.</a></li><li><a class="nounderline abstract_t">McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014; 22:363.</a></li><li><a class="nounderline abstract_t">Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64:465.</a></li><li><a class="nounderline abstract_t">Bruyère O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum 2016; 45:S3.</a></li><li><a class="nounderline abstract_t">Palma Dos Reis R, Giacovelli G, Girolami F, et al. Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials. Open Rheumatol J 2011; 5:69.</a></li><li><a class="nounderline abstract_t">Stepan JG, London DA, Boyer MI, Calfee RP. Blood glucose levels in diabetic patients following corticosteroid injections into the hand and wrist. J Hand Surg Am 2014; 39:706.</a></li><li><a class="nounderline abstract_t">Catalano LW 3rd, Glickel SZ, Barron OA, et al. Effect of local corticosteroid injection of the hand and wrist on blood glucose in patients with diabetes mellitus. Orthopedics 2012; 35:e1754.</a></li><li><a class="nounderline abstract_t">Kalafutova S, Juraskova B, Vlcek J. The impact of combinations of non-steroidal anti-inflammatory drugs and anti-hypertensive agents on blood pressure. Adv Clin Exp Med 2014; 23:993.</a></li><li><a class="nounderline abstract_t">Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121:289.</a></li><li><a class="nounderline abstract_t">Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002; 162:2204.</a></li><li><a class="nounderline abstract_t">Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum 2016; 45:S22.</a></li><li><a class="nounderline abstract_t">Hunter DJ. Viscosupplementation for osteoarthritis of the knee. N Engl J Med 2015; 372:1040.</a></li><li><a class="nounderline abstract_t">Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2005; :CD005321.</a></li><li><a class="nounderline abstract_t">McGarry JG, Daruwalla ZJ. The efficacy, accuracy and complications of corticosteroid injections of the knee joint. Knee Surg Sports Traumatol Arthrosc 2011; 19:1649.</a></li><li><a class="nounderline abstract_t">Ruyssen-Witrand A, Fautrel B, Saraux A, et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2011; 78:23.</a></li><li><a class="nounderline abstract_t">Furtado RN, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. J Rheumatol 2005; 32:1691.</a></li><li><a class="nounderline abstract_t">Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016; 375:2519.</a></li><li><a class="nounderline abstract_t">Roberts E, Delgado Nunes V, Buckner S, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2016; 75:552.</a></li><li><a class="nounderline abstract_t">Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006; 113:1578.</a></li><li><a class="nounderline abstract_t">Glasser SP, Khodneva Y. Should acetaminophen be added to the list of anti-inflammatory agents that are associated with cardiovascular events? Hypertension 2015; 65:991.</a></li><li><a class="nounderline abstract_t">Fulton RL, Walters MR, Morton R, et al. Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort. Hypertension 2015; 65:1008.</a></li><li><a class="nounderline abstract_t">Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162:276.</a></li><li><a class="nounderline abstract_t">Yusuf E, Nelissen RG, Ioan-Facsinay A, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis 2010; 69:761.</a></li><li><a class="nounderline abstract_t">Zambon S, Siviero P, Denkinger M, et al. Role of Osteoarthritis, Comorbidity, and Pain in Determining Functional Limitations in Older Populations: European Project on Osteoarthritis. Arthritis Care Res (Hoboken) 2016; 68:801.</a></li><li><a class="nounderline abstract_t">Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA 2013; 310:1263.</a></li><li><a class="nounderline abstract_t">Robson EK, Hodder RK, Kamper SJ, et al. Effectiveness of Weight-Loss Interventions for Reducing Pain and Disability in People With Common Musculoskeletal Disorders: A Systematic Review With Meta-Analysis. J Orthop Sports Phys Ther 2020; 50:319.</a></li><li><a class="nounderline abstract_t">Teichtahl AJ, Wluka AE, Tanamas SK, et al. Weight change and change in tibial cartilage volume and symptoms in obese adults. Ann Rheum Dis 2015; 74:1024.</a></li><li><a class="nounderline abstract_t">O'Neil CK, Hanlon JT, Marcum ZA. Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatr Pharmacother 2012; 10:331.</a></li><li><a class="nounderline abstract_t">Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010; 170:1979.</a></li></ol></div><div id="topicVersionRevision">Topic 109527 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31207113" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Comorbidities in Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26535137" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26312543" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : High prevalence of cardiovascular co-morbidities in patients with symptomatic knee or hand osteoarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24845389" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26464295" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21385807" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24608134" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33590469" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29157670" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Presence of comorbidities and prognosis of clinical symptoms in knee and/or hip osteoarthritis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32882828" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pain Trajectories in Knee Osteoarthritis-A Systematic Review and Best Evidence Synthesis on Pain Predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30908885" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Duration of Symptom Relief and Early Trajectory of Adverse Events for Oral Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462672" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : OARSI guidelines for the non-surgical management of knee osteoarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22563589" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26806188" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22216067" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24679910" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Blood glucose levels in diabetic patients following corticosteroid injections into the hand and wrist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23218632" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of local corticosteroid injection of the hand and wrist on blood glucose in patients with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25618128" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The impact of combinations of non-steroidal anti-inflammatory drugs and anti-hypertensive agents on blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8037411" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390063" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Frequency of analgesic use and risk of hypertension in younger women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26806184" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25760356" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Viscosupplementation for osteoarthritis of the knee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846754" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Viscosupplementation for the treatment of osteoarthritis of the knee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21222099" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The efficacy, accuracy and complications of corticosteroid injections of the knee joint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20471897" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16142862" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959716" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25732175" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Paracetamol: not as safe as we thought? A systematic literature review of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534006" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25801874" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Should acetaminophen be added to the list of anti-inflammatory agents that are associated with cardiovascular events?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25801870" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25581257" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487215" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association between weight or body mass index and hand osteoarthritis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26474272" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Role of Osteoarthritis, Comorbidity, and Pain in Determining Functional Limitations in Older Populations: European Project on Osteoarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24065013" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32272032" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effectiveness of Weight-Loss Interventions for Reducing Pain and Disability in People With Common Musculoskeletal Disorders: A Systematic Review With Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24519241" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Weight change and change in tibial cartilage volume and symptoms in obese adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23036838" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149754" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The comparative safety of opioids for nonmalignant pain in older adults.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
